MTOR and hereditary clear cell renal cell carcinoma: This analysis led to the identification of temsirolimus, a U.S. Food and Drug Administration (FDA)-approved mTOR inhibitor for renal cell carcinoma, which was repositioned from both stages of lung tumor cells and was tested in combination with thoracic radiation in NSCLC (Waqar et al., 2014).